Thu, Dec 18, 2014, 5:12 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celgene Corp. (CELG) Message Board

  • rob_cos rob_cos Aug 8, 2013 7:53 PM Flag

    Cancer " Len/dex significant benefit. 96% response" only 1.96% SPM rate. FRENCH STUDY (ironic)

    Cancer "Len/Dex combo is feasible for long-term use in patients with RRMM, with a significant benefit noted in terms of time to disease progression for prolonged treatment with Len/Dex - SPM rate only 1.96%...96% 3 yr response rate"(French Study! From a French study - the very country that made the SPM non-issue a temporary setback

    Cancer. 2013 Aug 6. doi: 10.1002/cncr.28274. [Epub ahead of print]
    Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T,Hulin C, Leleu X.
    Source ----- Hematology Department, Huriez Regional University Hospital, Lille, France.

    Abstract
    BACKGROUND: Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression. The objective of the current study was to determine the efficacy and safety profile of long-term exposure to Len/Dex.

    METHODS: A total of 50 patients with RRMM who were treated with long-term Len for ≥ 2 years from 2 Intergroupe Francophone du Myélome (IFM) centers (Lille and Nancy) were included in the current study

    RESULTS: The median age of the patients was 58 years, with 30% of the patients aged  65 years, 49% having an International Staging System stage of 2 and 3, 12% having severe renal insufficiency, and 8% demonstrating an adverse result on fluorescence in situ hybridization. Approximately 56% of the patients received treatment with Len/Dex for ≥ 3 years. The median duration of treatment with Len/Dex was 3 years (range, 2 years-7 years). The response rates for partial response or better and very good partial response or better for the overall cohort were 96% and 74%, respectively, which is similar to patients exposed to Len for ≥  (see results and Conclusion in reply)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • RESULTS:

      The median age of the patients was 58 years, with 30% of the patients aged  65 years, 49% having an International Staging System stage of 2 and 3, 12% having severe renal insufficiency, and 8% demonstrating an adverse result on fluorescence in situ hybridization. Approximately 56% of the patients received treatment with Len/Dex for ≥ 3 years. The median duration of treatment with Len/Dex was 3 years (range, 2 years-7 years). The response rates for partial response or better and very good partial response or better for the overall cohort were 96% and 74%, respectively, which is similar to patients exposed to Len for ≥ 3 years. With a median follow-up of 4 years, 19 (38%) patients had stopped treatment with Len/Dex. The time to disease progression rate at 37 months was 78% and 91%, respectively, in patients exposed to Len for 2 years to

 
CELG
116.48+3.66(+3.24%)Dec 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.